Document:

EX-10.3

 Exhibit 10.3 

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY 

AMENDMENT NO. 1 TO PROCESS DEVELOPMENT AGREEMENT 

This AMENDMENT NO. 1 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 21st day of April, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke
Road, Building 1 West Wing, ZhangJiang Hitech Park, Shanghai, China (“Tyligand”) and Context Therapeutics LLC, a Delaware limited liability company having its registered office at 3675 Market Street, Suite 200, Philadelphia,
PA 19104 (“Context”). Tyligand and Context are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Tyligand and Context entered into that certain Process Development Agreement, effective as of the 6th of March 2020 (the “Development Agreement”), which outlines the rights and obligations of Tyligand and Context with respect to the conduct of certain services to be performed
by Tyligand; 
 WHEREAS, the Parties wish to enter into this Amendment in order to amend certain provisions therein in accordance
with the terms and conditions set forth herein; 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
 1. Defined
Terms. All capitalized terms used herein shall have the meaning ascribed to each of them as defined herein and, if not defined herein, shall have the meaning ascribed to each of them in the Development Agreement. 

2. Amendment to Term of Development Agreement. Entered into as of the Amendment Effective Date, but effective as of the 6th day
of March 2021, the reference to “twelve (12) months” in Section 10.1 of the Development Agreement is hereby be amended and restated to instead be “fifteen (15) months”. 

3. Amendment to Section 2.8. Effective as of the Amendment Effective Date, Section 2.8 of the Development Agreement is
hereby amended and restated as follows: 
 “2.8. Technology Transfer and Assistance. Tyligand shall, upon the written request of
Context, transfer to Context all information, data, know-how, processes, and any other information comprising Intellectual Property and/or Know-How reasonably required
by Context to be able to conduct the Process. Furthermore, upon Successful Completion, Tyligand shall perform such technology transfer services, to Context and/or third party(ies) selected by Context based on the reasonable input from Tyligand,
including assisting Context in the review and analysis of potential third-party manufacturing site(s), on commercially reasonable terms as Context may reasonably request, which obligation to provide such services on commercially reasonable terms
shall survive the expiration or termination of this Agreement for a period of two (2) years. However, if the Agreement is terminated by Tyligand pursuant to Section 10.2 and 10.3 of the Agreement due to Context’s material breach,
insolvency or bankruptcy, then Tyligand shall not be obligated to provide such technology transfer services following termination of the Agreement. Context shall reimburse Tyligand for its reasonable cost associated with providing such
services.” 
 4. Amendment to Section 3.2. Effective as of the effective date of the Development Agreement, the
reference to “r3 in the second sentence of Section 3.2 is hereby amended and restated to be “fifteen”. 
 Certain
identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been omitted. 

  
 1 

 5. Amendment to Section 3.3. Effective as of the Amendment Effective
Date, Section 3.3 of the Development Agreement is hereby amended and restated as follows: 
 “3.3 [***]. Upon the
Successful Completion of the Development Plan in conformance with the Specifications during the Term, Context shall have its Affiliate, Context Therapeutics Inc., [***] 

6. Context represents and warrants to Tyligand that in connection with the [***] and the currently proposed corporate reorganization
transaction whereby Context intends to become a wholly-owned subsidiary of Context Therapeutics Inc., the ownership in Context Therapeutics Inc. immediately after such transaction is intended to be substantially similar to the ownership in Context
just prior to such transaction. 
 7. Change in Control to Affiliate. Tyligand hereby acknowledges and agrees that should
Context enter into any change in control and/or corporate reorganization transaction whereby Context becomes a wholly-owned subsidiary to any Affiliate, where the ownership in such Affiliate immediately after such transaction is substantially
similar to the ownership in Context just prior to such transaction, Section 10.4 shall not apply in connection with any such transaction. 

8. Entire Agreement. Each Party acknowledges that this Amendment, together with the Development Agreement, constitutes the
entire agreement of the Parties with respect to the subject matter hereof. 
 9. Full Force and Effect. Except as expressly
amended hereby, all of the other terms and conditions of the Development Agreement shall remain unchanged and in full force and effect in accordance with their original terms. 

10. Authority. Each Party hereby represents and warrants that is has full power and authority to enter into this Amendment. 

[Signature page follows] 

  
 2 

 IN WITNESS WHEREOF, the Parties have each caused a duly authorized representative to
execute this Amendment as of the Amendment Effective Date. 
  

									
	CONTEXT:	 		 	TYLIGAND:
			
	Context Therapeutics LLC	 		 	Tyligand Bioscience (Shanghai) Limited
					
	By:	 	/s/ Alex Levit	 		 	By:	 	 /s/ Tony Y. Zhang

					
	Name:	 	Alex Levit	 		 	Name:	 	Tony Y. Zhang
					
	Title:	 	Chief Legal Officer	 		 	Title:	 	Chief Executive Officer

  
 3EX-10.7

 Exhibit 10.7 

Context Therapeutics Inc. 
 2021
Long -Term Performance Incentive Plan 
 Stock Option Agreement 
  

	1.	 A Stock Option (the “Option”) for a total of
                     shares of $0.001 par value per share of Common Stock (the “Stock”) of Context Therapeutics Inc. (the
“Company”), is hereby granted to                      (the “Optionee”), subject to the terms and provisions of the Context
Therapeutics Inc. 2021 Long-Term Performance Incentive Plan (the “Plan”) insofar as the same are applicable to Stock Options granted thereunder. The terms and provisions of the Plan are incorporated herein by reference.

  

	2.	 The exercise price of the Option is $         per share which is equal
to 100% of the Fair Market Value (as defined in the Plan) of the Stock on the date of the grant of the Option, as determined pursuant to Section 3.2 of the Plan by the Compensation Committee of the Company’s Board of Directors (the
“Committee”) which has the authority for administering the Plan. 

  

	3.	 Subject to the provisions of Paragraphs 4 and 5 hereof, the Option may be exercised in whole at any time or in
part from time to time on or after the date the Option, or any portion thereof, first becomes exercisable. The Option terminates on the earlier of the date when fully exercised under the provisions of the Plan, the date fixed pursuant to
Section 3.7(a), 3.7(b), or 3.7(c) of the Plan, or                     . 

 

	4.	 The Option may not be exercised if the issuance of the Stock upon such exercise would constitute a violation of
any applicable Federal or state securities or other law or valid regulation. Further, exercise of an Option granted pursuant to this Agreement shall be under and subject to Paragraph 3.4 of the Plan. 

 

	5.	 This Option consists of the options identified below and shall be exercisable in accordance with the following
Schedule: 

  

					
	Options	  	Exercisable on or After	 
		  			

 Notwithstanding anything herein to the contrary, following termination of Optionee’s employment by the
Company or a Subsidiary of the Company for any reason not specified in Sections 3.7(a) or (b) of the Plan, the Option shall not be or become exercisable as to any shares other than those shares as to which the Option shall have been exercisable
in accordance with the preceding Schedule on the date of such termination.
  

	6.	 Except to the extent permitted under the Code or as provided by the Committee in its sole discretion, the
Option may not be transferred in any manner other than by will or the laws of descent or distribution and may be exercised during the lifetime of the Optionee only by him/her. The terms of the Option shall be binding upon the executors,
administrators, heirs, successors, and assigns of the Optionee.

  

	7.	 The Option may be exercised only upon payment of the full exercise price and all applicable withholding taxes,
and delivery of the completed “Notice of Exercise,” attached hereto, to the Secretary of the Company. Any attempted exercise of the Option without such delivery of the “Notice of Exercise” may be disregarded by the Company.
Payment and delivery for the purposes hereof may also be accomplished by making payment and delivery to an agent duly appointed by the Company for the purposes of accepting payment and notice of exercise. Where any such appointment is made, the
Company shall so advise Optionee, and Optionee may rely upon such notice until such notice is revoked or amended.

  
 1 

	8.	 Optionee shall have none of the rights of a shareholder with respect to any shares of Stock subject to the
Option, except as to the shares with respect to which Optionee has validly exercised the Option granted herein and tendered to the Company the full price therefor. 

 

	9.	 All notices required to be given hereunder shall be mailed by registered or certified mail to the Company to
the attention of its Secretary, at 3675 Market Street, Suite 200, Philadelphia, Pennsylvania 19104 and to Optionee at Optionee’s address as it appears on the Company’s books and records unless either of said parties has duly notified the
other in writing of a change in address. 

  

											
	                	 	OPTIONEE:	 		 		 	CONTEXT THERAPEUTICS INC.
					
		 	                                    
                            	 		 	By:	 	
                     
                    

				
	Date of Grant:                     	 		 		 	

 Optionee acknowledges receipt of a copy of the Plan, and represents that he/she is familiar with the terms and
provisions thereof, and hereby accepts the Option subject to the terms and provisions of the Plan insofar as they relate to Stock Options granted thereunder. Optionee agrees hereby to accept as binding, conclusive, and final all decisions or
interpretations of the Committee upon any questions arising under the Plan or the Option. Optionee authorizes the Company to withhold in accordance with applicable law from any compensation payable to him/her any taxes required to be withheld
by Federal, state, or local law as a result of the exercise of the Option. 
  

			
	By:	 	
                     
                                

  
 2 

 NOTICE OF EXERCISE 

To: Context Therapeutics Inc. (the “Company”) 
 The
undersigned hereby elects to exercise options for                      shares of Common Stock of Context Therapeutics Inc. (“Stock”),
pursuant to the terms of the attached Stock Option Agreement and the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan (the “Plan”). 

I hereby tender herewith payment in full of the exercise price for such shares and by one or more of the following methods: 

 

	☐	 Cash, check, bank draft or money order made payable to the order of the Company in the amount of
$        . 

  

	☐	 Enclosed are
                     shares of Stock with a total Fair Market Value (as defined in the Plan) on the date hereof of
$         pursuant to Section 3.5(b) of the Plan. 

  

	☐	 Please withhold
                     shares of Stock with a total Fair Market Value (as defined in the Plan) of $        
pursuant to the cashless exercise method in Section 3.5(b) of the Plan. 

  

	☐	 Payment through a broker-assisted exercise pursuant to Section 3(c) of the Plan (and I will provide such
information as requested by the Company). 

 Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below: 
  

							
		 	Name:	 	
                     
                    
	 	
		 	Address:	 	
                     
                    
	 	
		 		 	
                     
                    
	 	

  

									
	Date:	 	
                     
                    
	  		 	
                     
                    
	  	
		 		  		 	(Optionee)	  	

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]